Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

Aliment Pharmacol Ther 2011; 34: 462–469

[1]  J. Jahnsen,et al.  Fecal calprotectin variability in Crohn's disease. , 2010, Inflammatory bowel diseases.

[2]  J. Gisbert,et al.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? , 2010, Journal of Crohn's & colitis.

[3]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[4]  I. Ayadi,et al.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study , 2010, European journal of gastroenterology & hepatology.

[5]  M. Färkkilä,et al.  Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment , 2010, Scandinavian journal of gastroenterology.

[6]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[7]  A. Schoepfer,et al.  Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.

[8]  P. Renzulli,et al.  Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes , 2009, Inflammatory bowel diseases.

[9]  J. Mate,et al.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.

[10]  P. Rutgeerts,et al.  751e Adalimumab Induces and Maintains Mucosal Healing in Patients with Moderate to Severe Ileocolonic Crohn's Disease – First Results of the Extend Trial , 2009 .

[11]  H. Drummond,et al.  Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[12]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[13]  J. Mary,et al.  921 Long Term Follow-Up of a Cohort of Steroid-Dependent Crohn's Disease Patients Included in a Randomized Trial Evaluating Short Term Infliximab Combined with Azathioprine , 2008 .

[14]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[15]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[16]  R. Modigliani,et al.  A simple biological score for predicting low risk of short‐term relapse in Crohn's disease , 2006, Inflammatory bowel diseases.

[17]  L. Denson,et al.  Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[18]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[19]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[20]  T. Raivio,et al.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.

[21]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[22]  E. Irvine.  Patients' fears and unmet needs in inflammatory bowel disease , 2004 .

[23]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[24]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[25]  A. Røseth,et al.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.

[26]  L. Peyrin-Biroulet,et al.  Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[27]  M. Picco.  Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010 .

[28]  E. Irvine.  Review article: patients' fears and unmet needs in inflammatory bowel disease. , 2004, Alimentary pharmacology & therapeutics.